UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000026259 |
|---|---|
| Receipt number | R000029322 |
| Scientific Title | Phase II study for efficacy and safety of pembrolizumab for chemotherapy unfit previously untreated patients highly expressing PD-L1 positive advanced non-small cell lung cancer |
| Date of disclosure of the study information | 2017/03/27 |
| Last modified on | 2023/01/28 09:13:31 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/02/21 23:20:24 | ||
| 2 | Update | 2017/03/25 10:10:16 | Recruitment status |
|
| 3 | Update | 2017/03/25 10:10:48 | Date of disclosure of the study information |
|
| 4 | Update | 2017/05/04 01:34:53 | Anticipated trial start date |
|
| 5 | Update | 2017/07/17 16:36:11 | Recruitment status Anticipated trial start date |
|
| 6 | Update | 2018/05/20 10:03:53 | Recruitment status |
|
| 7 | Update | 2019/03/22 12:22:07 | Date of IRB Last follow-up date |
|
| 8 | Update | 2019/03/22 12:23:43 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Division name Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 9 | Update | 2023/01/28 09:13:31 | Recruitment status |
